Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Liabilities and Shareholders Equity (2016 - 2025)

OptimizeRx's Liabilities and Shareholders Equity history spans 16 years, with the latest figure at $170.3 million for Q3 2025.

  • For Q3 2025, Liabilities and Shareholders Equity rose 3.1% year-over-year to $170.3 million; the TTM value through Sep 2025 reached $678.5 million, down 2.76%, while the annual FY2024 figure was $171.2 million, 6.66% down from the prior year.
  • Liabilities and Shareholders Equity for Q3 2025 was $170.3 million at OptimizeRx, up from $169.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $183.4 million in Q4 2023 and bottomed at $121.3 million in Q2 2023.
  • The 5-year median for Liabilities and Shareholders Equity is $141.0 million (2021), against an average of $149.7 million.
  • The largest annual shift saw Liabilities and Shareholders Equity skyrocketed 144.17% in 2021 before it fell 17.72% in 2023.
  • A 5-year view of Liabilities and Shareholders Equity shows it stood at $141.0 million in 2021, then fell by 4.49% to $134.7 million in 2022, then surged by 36.18% to $183.4 million in 2023, then dropped by 6.66% to $171.2 million in 2024, then dropped by 0.49% to $170.3 million in 2025.
  • Per Business Quant, the three most recent readings for OPRX's Liabilities and Shareholders Equity are $170.3 million (Q3 2025), $169.3 million (Q2 2025), and $167.8 million (Q1 2025).